Published in J Pharmacol Exp Ther on August 01, 1998
Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol (2009) 1.56
Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta (2010) 1.53
A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. Am J Physiol Heart Circ Physiol (2003) 1.17
Adenosine receptors and reperfusion injury of the heart. Handb Exp Pharmacol (2009) 1.06
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor. J Med Chem (2011) 0.96
AMP579 is revealed to be a potent A2b-adenosine receptor agonist in human 293 cells and rabbit hearts. Basic Res Cardiol (2010) 0.83
Apyrase treatment of myocardial infarction according to a clinically applicable protocol fails to reduce myocardial injury in a porcine model. BMC Cardiovasc Disord (2010) 0.82
A(2A) adenosine receptor-mediated increase in coronary flow in hyperlipidemic APOE-knockout mice. J Exp Pharmacol (2011) 0.80
ATL 313, A Selective A(2A) Adenosine Receptor Agonist, Reduces Myocardial Infarct Size in a Rat Ischemia/Reperfusion Model. Open Cardiovasc Med J (2009) 0.77
Featured Article: Pharmacological postconditioning with delta opioid attenuates myocardial reperfusion injury in isolated porcine hearts. Exp Biol Med (Maywood) (2016) 0.75
Polyphenol (-)-epigallocatechin gallate-induced cardioprotection may attenuate ischemia-reperfusion injury through adenosine receptor activation: a preliminary study. Korean J Anesthesiol (2012) 0.75
Adenosine A2A receptor agonist prevents cardiac remodeling and dysfunction in spontaneously hypertensive male rats after myocardial infarction. Drug Des Devel Ther (2017) 0.75
Inhibitory effects of AMP 579, a novel cardioprotective adenosine A1/A2A receptor agonist, on native IKr and cloned HERG current. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.75
The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev (1999) 14.43
Chlamydia trachomatis infections in female military recruits. N Engl J Med (1998) 4.68
Signal transduction through homologs of the Ste20p and Ste7p protein kinases can trigger hyphal formation in the pathogenic fungus Candida albicans. Proc Natl Acad Sci U S A (1996) 3.50
A putative modular domain present in diverse signaling proteins. Cell (1993) 2.90
The yeast transcription activator PRTF, a homolog of the mammalian serum response factor, is encoded by the MCM1 gene. Genes Dev (1989) 2.89
Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome. EMBO J (1998) 2.81
Hepatocyte nuclear factor 3/fork head or "winged helix" proteins: a family of transcription factors of diverse biologic function. Proc Natl Acad Sci U S A (1993) 2.47
The Saccharomyces cerevisiae WRN homolog Sgs1p participates in telomere maintenance in cells lacking telomerase. EMBO J (2001) 1.99
Restructuring the neuronal stress response with anti-glucocorticoid gene delivery. Nat Neurosci (2004) 1.72
Physiological adaptations to a weight-loss dietary regimen and exercise programs in women. J Appl Physiol (1985) (1997) 1.50
Sir2: an NAD-dependent histone deacetylase that connects chromatin silencing, metabolism, and aging. Cold Spring Harb Symp Quant Biol (2000) 1.41
Mutation of the hamster cell cycle gene RCC1 is complemented by the homologous genes of Drosophila and S.cerevisiae. EMBO J (1991) 1.39
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol (2001) 1.37
An enzootic transmission cycle of Lyme borreliosis spirochetes in the southeastern United States. Proc Natl Acad Sci U S A (2003) 1.36
Two classes of sir3 mutants enhance the sir1 mutant mating defect and abolish telomeric silencing in Saccharomyces cerevisiae. Genetics (2000) 1.30
Evidence for L-glutamate as the neurotransmitter of baroreceptor afferent nerve fibers. Science (1980) 1.29
Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res (1992) 1.28
Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol (1988) 1.25
Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol (1991) 1.20
Isolation, cultivation, and characterization of Borrelia burgdorferi from rodents and ticks in the Charleston area of South Carolina. J Clin Microbiol (2000) 1.19
Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol (1993) 1.17
Demonstration of vasorelaxant activity with an A1-selective adenosine agonist in porcine coronary artery: involvement of potassium channels. J Pharmacol Exp Ther (1992) 1.17
Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist. Br J Pharmacol (1992) 1.12
Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol (2007) 1.12
Genetic heterogeneity of Borrelia burgdorferi sensu lato in the southern United States based on restriction fragment length polymorphism and sequence analysis. J Clin Microbiol (2001) 1.12
Geographic survey of vector ticks (Ixodes scapularis and Ixodes pacificus) for infection with the Lyme disease spirochete, Borrelia burgdorferi. J Vector Ecol (1999) 1.09
Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design. J Med Chem (2001) 1.09
ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. J Pharmacol Exp Ther (2000) 1.09
Creatine supplementation enhances muscular performance during high-intensity resistance exercise. J Am Diet Assoc (1997) 1.08
Histone-like transcription factors in eukaryotes. Curr Opin Struct Biol (1997) 1.07
RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther (1997) 1.03
Direct evidence for the role of neuropeptide Y in sympathetic nerve stimulation-induced vasoconstriction. Am J Physiol (1998) 1.03
BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction. CNS Drug Rev (2003) 1.02
Genetic identification of residues involved in association of alpha and beta G-protein subunits. Mol Cell Biol (1994) 1.02
Characterization of human PLD2 and the analysis of PLD isoform splice variants. FASEB J (1998) 1.00
Using yeast to discover the fountain of youth. Sci Aging Knowledge Environ (2001) 1.00
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol (2007) 0.96
An improved method of evaluation of drug-evoked changes in gastric emptying in mice. J Pharmacol Toxicol Methods (2002) 0.95
Effect of potent urease inhibitor, fluorofamide, on Helicobacter sp. in vivo and in vitro. Dig Dis Sci (1998) 0.94
Ectoparasite fauna of the eastern woodrat, Neotoma floridana: composition, origin, and comparison with ectoparasite faunas of western woodrat species. J Parasitol (1997) 0.93
Characterization of isoleucyl-tRNA synthetase from Staphylococcus aureus. II. Mechanism of inhibition by reaction intermediate and pseudomonic acid analogues studied using transient and steady-state kinetics. J Biol Chem (1998) 0.93
Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant (1999) 0.92
Comparative study of AMP579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury during 24 h of reperfusion. Cardiovasc Res (2000) 0.92
Acute hypertension after the local injection of kainic acid into the nucleus tractus solitarii of rats. Circ Res (1981) 0.91
Effects of peptidase inhibition on angiotensin receptor agonist and antagonist potency in rabbit isolated thoracic aorta. Br J Pharmacol (1992) 0.90
Inhibition of EGF-induced vasoconstriction in isolated rabbit aortic rings with the tyrosine kinase inhibitor RG50864. Biochem Biophys Res Commun (1993) 0.90
Regulation of pituitary receptors for thyrotropin-releasing hormone by thyroid hormones. J Biol Chem (1978) 0.89
Phenylephrine protects neonatal rat cardiomyocytes from hypoxia and serum deprivation-induced apoptosis. Cell Death Differ (2000) 0.89
Foot-and-mouth disease virus in semen of bulls and its transmission by artificial insemination. Arch Gesamte Virusforsch (1968) 0.89
Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H(1) and H(3) receptors. Br J Pharmacol (2011) 0.88
Influence of exercise training on physiological and performance changes with weight loss in men. Med Sci Sports Exerc (1999) 0.88
Evidence that glutamic acid is the neurotransmitter of baroreceptor afferent terminating in the nucleus tractus solitarius (NTS). J Auton Nerv Syst (1981) 0.88
Pharmacological analysis of alpha-2 adrenergic mechanisms in nociception and ataxia. J Pharmacol Exp Ther (1985) 0.88
Penicillin-Sensitive Mutants Arising from Penicillin-Resistant Staphylococcus Aureus During the Course of Experimental Canine Endocarditis. Trans Am Clin Climatol Assoc (1959) 0.88
Biochemical evidence that L-glutamate is a neurotransmitter of primary vagal afferent nerve fibers. Brain Res (1981) 0.86
Randomized surgical adjuvant trial of interferon alfa-n1 in recurrent papillomatosis. Arch Otolaryngol Head Neck Surg (1988) 0.85
Genetic interaction of DED1 encoding a putative ATP-dependent RNA helicase with SRM1 encoding a mammalian RCC1 homolog in Saccharomyces cerevisiae. Mol Gen Genet (1996) 0.84
In vitro and in vivo characterization of an A1-selective adenosine agonist, RG14202. J Pharmacol Exp Ther (1993) 0.84
Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocin-treated rats. J Cardiovasc Pharmacol (1997) 0.84
Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain. Eur J Pharmacol (1990) 0.84
Characterization of three non-peptide endothelin receptor ligands using human cloned ETA and ETB receptors. Br J Pharmacol (1994) 0.84
Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J Pharmacol Exp Ther (1989) 0.83
BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol (2009) 0.83
Phorbol-12,13-dibutyrate-induced vasoconstriction in vivo: characterization of response in genetic hypertension. J Pharmacol Exp Ther (1990) 0.83
Pharmacological characterization of P2X7 receptors in rat peritoneal cells. Inflamm Res (2005) 0.83
Selective adenosine-2 agonist produces both direct and reflex tachycardia in normotensive rats. J Cardiovasc Pharmacol (1992) 0.83
Profile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model. Thromb Haemost (1999) 0.83
Relationships between thyroid hormone and glucocorticoid effects in GH3 pituitary cells. Endocrinology (1980) 0.83
Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: coronary hemodynamic and cardioprotective effects in the canine myocardium. J Cardiovasc Pharmacol (1999) 0.82
Mystery of the toxic flea dip: an interactive approach to teaching aerobic cellular respiration. Cell Biol Educ (2004) 0.82
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines. J Med Chem (1987) 0.82
Prior knee injury and risk of future hospitalization and discharge from military service. Am J Prev Med (2000) 0.82
In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor. Eur J Pharmacol (1992) 0.82
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery. Thromb Haemost (1997) 0.81
Identification and characterization of substance P receptors on LRM55 glial cells. J Pharmacol Exp Ther (1986) 0.81
Non-invasive characterization of beta-amyloid(1-40) vasoactivity by functional magnetic resonance imaging in mice. Neuroscience (2008) 0.81
Endothelin and ET(A) receptors in long-term arterial pressure homeostasis in conscious nonhuman primates. Am J Physiol Regul Integr Comp Physiol (2000) 0.81
Differential alteration of vascular reactivity in rabbit aorta with modest elevation of serum cholesterol. Circ Res (1990) 0.81
Antagonism of the baroreceptor reflex by glutamate diethyl ester, an antagonist to L-glutamate. Brain Res (1981) 0.80
Angiotensin II-dependent hypertension and the arterial baroreflex. Clin Exp Hypertens (1995) 0.80
Identification of a tRNA(Gln) ochre suppressor in Saccharomyces cerevisiae. Nucleic Acids Res (1992) 0.80
Binding of [3H]substance P to putative substance P receptors in rat brain membranes. Eur J Pharmacol (1983) 0.80
1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittelforschung (1996) 0.80
Differential effects of the adenosine A(1) receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes. Brain Res (1999) 0.80
A novel adenosine analog, AMP579, inhibits neutrophil activation, adherence and neutrophil-mediated injury to coronary vascular endothelium. Eur J Pharmacol (2000) 0.79
Mechanism of thyroid hormone inhibition of thyrotropin-releasing hormone action. Endocrinology (1981) 0.79
Protein kinase C and vascular smooth muscle contractility: effects of inhibitors and down-regulation. J Pharmacol Exp Ther (1991) 0.79
A comparison of the cardiovascular effects of phenylpropanolamine and phenylephrine containing proprietary cold remedies. Br J Clin Pharmacol (1991) 0.79
Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin. Arterioscler Thromb Vasc Biol (1998) 0.79
Life cycle of Ixodes minor (Acari: Ixodidae) in the laboratory. J Med Entomol (1998) 0.79
Thyroid hormone action in pituitary cells. Differences in the regulation of thyrotropin-releasing hormone receptors and growth hormone synthesis. J Biol Chem (1979) 0.79
RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase. Naunyn Schmiedebergs Arch Pharmacol (1996) 0.79
Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs. Thromb Res (2001) 0.79
Differential regulation of sympathetic nerve activity by lateral and medial subregions of the rostral ventral medulla. Prog Brain Res (1989) 0.78
Regional hemodynamic dose-response of lemakalim and glybenclamide in anesthetized rats. J Cardiovasc Pharmacol (1997) 0.78